Switching between GLP-1 medications There are a few reasons why your clinician may suggest switching GLP-1s
Circulation 127 , 7485 (2013)
So when a drug goes under shortage, that essentially gives authority to these compounders to start producing them, you know, to fill in these access gaps
The use of GLP-1 agonists in the management of cutaneous disease
In a statement, Scott Brunner, CEO of the Alliance for Pharmacy Compounding, questioned whether the FDA's resolution of the shortage had taken into account demand for the compounded drug and "the number of patients wholl need to be transitioned from a compounded version to a FDA-approved version. "Thats likely hundreds of thousands of patients," Brunner said
Holding onto muscle translates to a speedier metabolism and more sustainable results